Holen Sie sich die Stockscreener-App
69.41
2.10%
1.43
Handel nachbörslich:
69.41
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
BridgeBio Pharma Touts Attruby Uptake, Bayer’s Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf - Yahoo Finance
BridgeBio Pharma CEO Teases Pipeline Launches, Attruby Momentum, and Pfizer Tafamidis Trial Update - Yahoo Finance
BridgeBio Looks At Genetic Testing To Build Out BBP-418 Launch In LGMD2I/R9 - Citeline News & Insights
A Look At BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility - simplywall.st
BridgeBio reports Phase III progress for BBP-418 - The Pharmaletter
BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress - Benzinga
Barclays Maintains Overweight on BridgeBio Pharma (BBIO) March 2026 - Meyka
Capital Research Global Investors Sells 2,055,172 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Leerink Maintains Outperform on BBIO, BridgeBio Pharma, Inc. March 12, 2026 - Meyka
BridgeBio (BBIO) Reports Promising Phase 3 Data for BBP-418 in M - GuruFocus
BridgeBio Pharma Presents Promising Phase 3 FORTIFY Interim Analysis Results for BBP-418 in LGMD2I/R9 at MDA Conference - Quiver Quantitative
Bridgebio Pharma Plans To Submit NDA For BBP-418 To FDA In H1 2026 - TradingView
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 - GlobeNewswire Inc.
BridgeBio (BBIO) Reports Wider Q4 Loss of $1/Share vs $0.63 Estimate; Stock Surges 13% - AlphaStreet
HC Wainwright Raises Earnings Estimates for BridgeBio Pharma - MarketBeat
BridgeBio (BBIO) Sees Price Target Boost and Earns Overweight Ra - GuruFocus
BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade - Insider Monkey
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat
U.S. Indexes Finished Mixed Tuesday As BridgeBio Pharma Led, Centene Lagged - Barron's
Barclays reiterates Overweight on BridgeBio Pharma stock By Investing.com - Investing.com Canada
BridgeBio’s Price Target Boost Sparks Investor Excitement - StocksToTrade
Why Is BridgeBio Pharma Stock Soaring Tuesday?BridgeBio Pharma (NASDAQ:BBIO) - Benzinga
JP Morgan Raises Price Target for BridgeBio Pharma (BBIO) to $94 - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Trading Up 9.3%Should You Buy? - MarketBeat
BridgeBio Pharma shares jump as investors focus on fresh BBP-418 data at MDA meeting and near-term regulatory milestones - Quiver Quantitative
BridgeBio Pharma’s Surge: A Closer Look at Market Dynamics - StocksToTrade
BridgeBio Pharma’s Growth Momentum Backed by Analyst Confidence - timothysykes.com
BridgeBio Pharma Jumps as Wall Street Piles In - TipRanks
William Blair initiates BridgeBio stock with outperform rating - Investing.com India
William Blair initiates BridgeBio stock with outperform rating By Investing.com - Investing.com South Africa
BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Analysts at William Blair - MarketBeat
FY2027 Earnings Estimate for BBIO Issued By HC Wainwright - MarketBeat
Victory Capital Management Inc. Purchases 141,800 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz - Bitget
Does Positive Phase 3 BBP-418 Data in LGMD2I/R9 Change The Bull Case For BridgeBio Pharma (BBIO)? - Yahoo Finance
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How The BridgeBio Pharma (BBIO) Narrative Is Shifting With Attruby And Late Stage Pipeline - Yahoo Finance
Andrea Ellis Sells 64,921 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat
BridgeBio Pharma director Ellis Andrea sells $4.2m in shares - Investing.com South Africa
BridgeBio Pharma director Ellis Andrea sells $4.2m in shares By Investing.com - Investing.com UK
Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating - Bitget
(BBIO) Movement as an Input in Quant Signal Sets - Stock Traders Daily
GW&K Investment Management LLC Takes Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma Talks Atrubie Momentum, Phase 3 Wins as Tafamidis IP Trial Looms - MarketBeat
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference - Bitget
BridgeBio Pharma to Present Phase 3 FORTIFY Trial Data on LGMD2I/R9 Therapy at 2026 MDA Conference - geneonline.com
BridgeBio to present LGMD2I/R9 trial data at MDA conference By Investing.com - Investing.com Australia
[144] BridgeBio Pharma, Inc. SEC Filing - Stock Titan
BridgeBio to present LGMD2I/R9 trial data at MDA conference - Investing.com Nigeria
TD Asset Management Inc Purchases Shares of 88,950 BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. (BBIO) Latest Stock News & Headlines - Yahoo Finance
BridgeBio Pharma to Present New Data on BBP-418 for LGMD2I/R9 at MDA Conference - Quiver Quantitative
Aisling Capital Management LP Has $316.29 Million Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma Director Sells Shares - TradingView
BridgeBio (BBIO) director sells 25,484 shares after option exercise - Stock Titan
BBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rafferty Asset Management Reduces Stake in BridgeBio Pharma - National Today
Rafferty Asset Management LLC Sells 44,792 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by Attruby Commercial Success - Bitget
Intech Investment Management Trims BridgeBio Pharma Stake - National Today
A Look At BridgeBio Pharma (BBIO) Valuation After Phase 3 Wins And Attruby Commercial Momentum - simplywall.st
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Unpacking a 50.49% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Intech Investment Management LLC Sells 19,826 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):